PaxMedica is a biotechnology business based in the US. PaxMedica shares (PXMD) are listed on the NASDAQ and all prices are listed in US Dollars. PaxMedica employs 2 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.22 |
|---|---|
| 52-week range | $1.36 - $10.48 |
| 50-day moving average | $2.08 |
| 200-day moving average | $2.45 |
| Wall St. target price | N/A |
| PE ratio | 17.6 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.15 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.22 from 2024-07-23
| 1 week (2024-07-19) | -9.84% |
|---|---|
| 1 month (2024-06-26) | 0.22 |
| 3 months (2024-04-26) | -70.26% |
| 6 months (2024-01-26) | -56.00% |
| 1 year (2023-07-26) | -69.32% |
|---|---|
| 2 years (2022-07-22) | N/A |
| 3 years (2021-07-22) | N/A |
| 5 years (2019-07-22) | N/A |
Valuing PaxMedica stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of PaxMedica's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
PaxMedica's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, PaxMedica shares trade at around 18x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -118.29% |
| Return on equity TTM | 0% |
| Profit margin | 0% |
| Book value | $0.20 |
| Market Capitalization | $31.8 million |
TTM: trailing 12 months
We're not expecting PaxMedica to pay a dividend over the next 12 months.
PaxMedica, Inc. , a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human African trypanosomiasis (HAT). It also develops PAX-102, an intranasal formulation of suramin for neurologic indications; and HAT-301 for the treatment of stage 1 East African HAT. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc.
Steps to owning and managing ZTEK, with 24-hour and historical pricing before you buy.
Steps to owning and managing MYNZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing ATAI, with 24-hour and historical pricing before you buy.
Steps to owning and managing OWLT, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing HUM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ILMN, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.